Skip to content

Hormonal Status, Performance and Health in Elite Female Athlete

Menstrual Cycle, Amenorrhea and Contraception in Elite Female Athletes: Impact on Performance, Health and the Athlete's Biological Passport

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05028959
Acronym
FEMMES
Enrollment
80
Registered
2021-08-31
Start date
2021-09-15
Completion date
2025-05-31
Last updated
2021-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

female elite athlete, menstrual phase, amenorrhea, hormonal contraception, performance, health, Athlete Biological Passport

Brief summary

The repercussions of the hormonal status of high-level sportswomen on their performance and health as well as on the Athlete's Biological Passport (ABP) have been little studied and remain poorly known. The investigators therefore propose to contribute to the improvement of current knowledge by determining, thanks to the implementation of a multidisciplinary monitoring, with the use of various tests and matrices, in female elite athletes and recreational athletes (control group): * 1\) the impact of cycle phase, absence of cycle or contraceptive use on physical and psychological performance, health as well as on ABP; * 2\) the potential confounding effects of the athlete's environment * 3\) correlations between the different matrices analyzed

Detailed description

Volunteers to be studied: 80 healthy female subjects (16 to 30 years old), divided into 2 groups: Group 1: 60 athletes, from different sports disciplines, in amenorrhea, with menstrual cycle or taking contraceptives Group 2: 20 leisure sports subjects with menstrual cycle or taking contraceptives Following the oral and written information of the project, the subjects have a minimum of 15 days of reflection before signing the written consent form. They will have the possibility, at any time, to voluntarily interrupt the study without having to justify themselves. Investigations to be performed: 1. Annual complete clinical examination : 2. Out-of-competition follow-up, time frame 6 months * medical, nutritional and respiratory monitoring * biological monitoring * psychological monitoring * performance monitoring 3. Non-invasive in-competition monitoring, only for Group 1, once in a year on the day before/after a major competition: * biological monitoring * psychological monitoring * performance monitoring (interview)

Interventions

OTHERMultidisciplinary monitoring of healthy women

Multidisciplinary monitoring

Sponsors

Université Paris-Saclay-Assistance publique des hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

2 groups : female athletes and leisure sports women

Eligibility

Sex/Gender
FEMALE
Age
16 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* Group 1: high-level athletes (qualified for national/international championships and/or training at least 15 hours/week) * Group 2: recreational athletes who practice a regular physical activity

Exclusion criteria

* Participation in another trial * History of cardiac pathology * High blood pressure * History of ulcers and other gastrointestinal disorders * Myasthenia * Renal insufficiency * Person not affiliated or not benefiting from a social security system

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline inflammatory parameters6 monthsconcentration of cytokines (TNF-alpha, IL-6) in mol/L
Change from baseline weight6 monthsin kg, by impedancemeter
Change from baseline fat and lean mass6 monthsin kg, by impedancemeter
Change from baseline height6 monthsin cm, by height gauge
Change from baseline sex and stress hormones6 monthsconcentration of oestradiol, progesterone, testosterone, DHEA, cortisol, LH and FSH in mol/L
Change from baseline food intake6 monthsfood intake questionnaire to complete over 3 days, expressed in kcal/day
Change from baseline metabolic parameters6 monthsconcentration of blood glucose, blood lactate, lipid profile, insulin, GH, IGF1, T3, IgA, PRL and leptin in mol/L
Change from baseline respiratory parameters6 monthsmeasure of FEV1 (forced expiratory volume in 1 second), expressed in % of vital capacity
Change from baseline executive function6 monthsassessed by instability via static and dynamic postures (eyes open/closed) on platform
Change from baseline visual-spatial processing6 months3 D mental rotation test, assessed by scores: range from 0 - 24, with 24 representing a perfect total score
Change from baseline attention and working memory6 monthsStroop Color Word Task, assessed by scores : range of interference from -15 - +15, with higher scores representing decreased selective attention
Change from baseline performance monitoring6 monthsfield performance test, performance expressed in time
Change from baseline Athlete Biological Passport (Group 2)6 monthsassessed by analysis of the standardized parameters of the Athlete Biological Passport (WADA)
Change from baseline affects (Group 2)6 monthsPositive Affect and Negative Affect Schedule (PANAS), assessed by scores. Positive Affect Score: range from 10 - 50, with higher scores representing higher levels of positive affect. Negative Affect Score: range from 10 - 50, with lower scores representing lower levels of negative affect.
Change from baseline anxiety (Group 2)6 monthsSpielberger State-Trait Anxiety Inventory, assessed by scores: range from 20 - 80, with higher scores representing higher anxiety
Change from baseline Athlete Biological Passport (Group 1)8 monthsassessed by analysis of the standardized parameters of the Athlete Biological Passport (WADA)
Change from baseline affects (Group 1)8 monthsPositive Affect and Negative Affect Schedule (PANAS), assessed by scores. Positive Affect Score: range from 10 - 50, with higher scores representing higher levels of positive affect. Negative Affect Score: range from 10 - 50, with lower scores representing lower levels of negative affect.
Change from baseline anxiety (Group 1)8 monthsSpielberger State-Trait Anxiety Inventory, assessed by scores: range from 20 - 80, with higher scores representing higher anxiety
Interview (Group 1)8 monthsSelf-confrontation interview for questioning the action

Contacts

Primary ContactEmmanuelle DURON, PU-PH
emmanuelle.duron@aphp.fr33144083503
Backup ContactChristine Le-Scanff, PU
christine.le-scanff@universite-paris-saclay.fr33169156198

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026